| Name | TRPV1 |
|---|---|
| Synonyms | Capsaicin receptor; OTRPC 1; Osm 9 like TRP channel 1; TRP vanilloid 1; TRPV 1; TRPV1; Transient receptor potential cation channel subfamily V member 1… |
| Name | biphenyl |
|---|---|
| CAS | 1,1′-biphenyl |
| PubMed | Abstract | RScore(About this table) | |
|---|---|---|---|
| 18809416 | Tang HB, Li YS, Miyano K, Nakata Y: Phosphorylation of TRPV1 by neurokinin-1 receptor agonist exaggerates the -mediated substance P release from cultured rat dorsal root ganglion neurons. Neuropharmacology. 2008 Dec;55(8):1405-11. Epub 2008 Sep 17. |
5(0,0,0,5) | Details |
| 18027904 | Ortar G, Cascio MG, De Petrocellis L, Morera E, Rossi F, Schiano-Moriello A, Nalli M, de Novellis V, Woodward DF, Maione S, Di Marzo V: New N-arachidonoylserotonin analogues with potential "dual" mechanism of action against pain. J Med Chem. 2007 Dec 27;50(26):6554-69. Epub 2007 Nov 21. N-arachidonoylserotonin (AA-5-HT, 1a) is an inhibitor of fatty acid amide hydrolase (FAAH) that acts also as an antagonist of transient receptor potential vanilloid-type 1 (TRPV1) channels and is analgesic in rodents. |
4(0,0,0,4) | Details |
| 18695637 | Ho WS, Barrett DA, Randall MD: 'Entourage' effects of N-palmitoylethanolamide and N-oleoylethanolamide on vasorelaxation to occur through TRPV1 receptors. Br J Pharmacol. 2008 Nov;155(6):837-46. Epub 2008 Aug 11. PEA and inhibition of hydrolysis by 3'-carbamoyl-biphenyl-3-yl-cyclohexylcarbamate (URB597) (1 microM) additively potentiated responses. |
3(0,0,0,3) | Details |
| 19289116 | Garcia Mdel C, Adler-Graschinsky E, Celuch SM: Enhancement of the hypotensive effects of intrathecally injected endocannabinoids by the entourage compound palmitoylethanolamide. Eur J Pharmacol. 2009 May 21;610(1-3):75-80. Epub 2009 Mar 14. The hypotensive response induced by co-administration of palmitoylethanolamide and 25 nmol was prevented both by the cannabinoid CB (1) receptor antagonist SR 144716A (20 nmol; i.t.) and by the vanilloid TRPV1 receptor antagonist capsazepine (20 nmol; i.t.) and enhanced by pretreatment with URB602 (3.5 nmol; i.t.), a putative inhibitor of palmitoylethanolamide degradation. |
2(0,0,0,2) | Details |